# Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis

> **NCT02476279** · PHASE3 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 1950 (actual)

## Conditions studied

- Post-ERCP Pancreatitis

## Interventions

- **OTHER:** Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement
- **OTHER:** Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement

## Key facts

- **NCT ID:** NCT02476279
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-01-25
- **Target enrollment:** 1950 (ACTUAL)
- **Last updated:** 2024-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476279, "Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02476279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*